Improving care for cancer survivors with chronic conditions
Official title: Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities
Run by Baylor College of Medicine · NCT05323409 · Data updated 2026-11-12
This study is testing a new care approach to see if it can help cancer survivors with other health issues get better support and improve their overall health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 340 (estimated) |
| Sponsor | Baylor College of Medicine Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | April 1, 2022 |
| Main results expected | May 2027 |
| Study ends | June 2027 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT05323409 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with a recent diagnosis of early-stage breast, gastrointestinal, or hematologic cancer, who also have one or more chronic comorbidities.
✕Probably not a fit
Patients with significant cognitive impairment or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates a new shared care model called OPTIMISE, designed to enhance the comprehensive care of cancer survivors who also have chronic comorbidities. The study involves a randomized controlled trial with 300 medically underserved patients diagnosed with breast, gastrointestinal, or hematologic cancers. Participants will be divided into two groups: one receiving standard care and the other receiving the OPTIMISE intervention, which includes tailored self-management plans and improved communication between oncologists and primary care providers. The trial aims to assess the effectiveness of this model in improving health outcomes and care transitions for these patients.
Why it matters
Potential benefit: If successful, this approach could significantly improve the health outcomes and quality of life for cancer survivors with chronic conditions.
How similar studies have gone: Other studies have shown promise in improving care transitions and outcomes for cancer survivors, suggesting that this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2) treatment with standard, definitive therapies (may include one or more modalities) 3) presence of one or more chronic comorbidities (e.g., diabetes, hypertension) and/or unhealthy lifestyle behaviors (e.g., overweight/obesity, current smoker, alcohol use) that require ongoing management during cancer treatment 4) age \>18 years 5) fluency in English or Spanish 6) ability to provide informed consent 7) assignment to a Harris Health oncologist and PCP who are willing to participate and will provide informed consent. For healthcare providers: 1) Person is an oncologist or PCP who treats patients with breast, GI, or hematologic malignancies at Harris Health BT/Smith Clinic Exclusion Criteria: * For Patients: Significant cognitive impairment or Lack of capacity to consent For Providers: None
Where it's running
-
Baylor College of Medicine
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Hoda Badr — Baylor College of Medicine
- Study coordinator: Hoda J. Badr, PhD
- Email: hoda.badr@bcm.edu
- Phone: 7137981588
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood extracellular vesicles to detect chemotherapy-related nerve damage.
We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.
-
High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)
This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.
-
Florida ASCENT Program
This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.
-
18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers
We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.
-
Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma
This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.
-
Injecting engineered immune cells to treat advanced solid tumors
This study is testing a new treatment that uses specially modified immune cells taken from patients' tumors to see if it can help people with advanced cancers that haven't responded to other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.